Date: Jan 30, 2001 Source: Company Data
DENVER, Jan. 30 /PRNewswire/ -- Invenux, Inc., a privately held drug discovery company, announced today that it has named Carl A. Pelzel as
president and chief executive officer. Pelzel joined Invenux in March 2001 as president and chief executive officer of the company's wholly owned subsidiary, Evolutionary Medicine, which consolidated with Invenux in December 2001. Pelzel will oversee the company's efforts to fully leverage the potential of its proprietary technology, Evolutionary Chemistry(TM) in the field of pharmaceuticals.
"With the consolidation of Evolutionary Medicine and Invenux, we have streamlined our operations and are better equipped to maximize the commercial value of the compounds discovered through Evolutionary Chemistry," Pelzel said. "We are currently focused on advancing research and development for the first Evolutionary Chemistry-derived compounds, which are the only known monobactam antibiotics with gram positive activity."
Prior to joining Invenux, Pelzel held numerous high-level positions at GlaxoSmithKline (formerly GlaxoWellcome, Inc.), including vice president of sales and marketing for the U.S. HIV and Oncology Division; vice president of international commercial development for HIV; country manager, China; general manager of operations, Hong Kong; and director in the group commercial strategy directorate in London. While in Asia, he also served as president ofthe Pharmaceutical Association in Hong Kong. Previously, Pelzel held sales and marketing positions for 13 years at Lederle Laboratories, including director of marketing for anti-infectives.
Pelzel replaces founder Bruce Eaton, Ph.D., who will continue with thecompany as senior vice president of technology advancement and a member of the board of directors.
nvenux, Inc.
Founded in February 2000, Denver-based Invenux, Inc. is a privately held drug discovery company utilizing proprietary, breakthrough technology that has the potential to deliver active, specific compounds for virtually any therapeutic target. Invenux's core technology is Evolutionary Chemistry -- a
technology that promises to significantly streamline the drug discovery process by selecting only the most promising leads from millions of compounds.
For more information, please visit www.invenux.com .
